Category: Pharma Industry

Paper Warns on Duplicate Discounts from 340B Ceiling Price, Medicare Maximum Price

October 19, 2023 Tom Mirga, Editor at Large Views

An Avalere study suggested 340B duplicate discounts could increase as a result of Medicare drug price negotiations.

Timelines for manufacturers to provide new Medicare “maximum fair prices” (MFPs) and 340B ceiling prices on drugs are misaligned, risking [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Eisai’s New 340B Contract Pharmacy Restrictions to Exclude Arkansas and Louisiana

October 17, 2023 William Newton, Associate Editor/Senior Writer Views

Drugmaker Eisai's 340B hospital contract pharmacy restrictions will not apply to Arkansas and Louisiana providers.

Japanese pharmaceutical manufacturer Eisai will not limit hospital 340B contract pharmacy use in Arkansas and Louisiana after its new contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

New BMS Contract Pharmacy Policy May Target Hospital Self-Distribution, Say Attorneys

October 17, 2023 Rich Daly, Editor in Chief Views

William von Oehsen, principal at the law firm Powers, said the SUSTAIN ACT is "not going to live or die based on the user fee."

Drugmaker Bristol Myers Squibb added new language to its latest 340B contract pharmacy policy notice, which appears to target hospital [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Novo Nordisk Files Suit to Block $100,000 Arkansas Fine for 340B Contract Pharmacy Violations

October 13, 2023 William Newton, Associate Editor/Senior Writer Views

Novo Nordisk and the Arkansas Insurance Department are at odds over whether a federal district court should intervene in the enforcement of Arkansas' 340B contract pharmacy law.

Danish drug giant Novo Nordisk filed suit Thursday to stop a proposed $100,000 fine from Arkansas over alleged violations of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

HRSA Audit Finds Fourth Drugmaker Owes Refunds

October 13, 2023 Rich Daly, Editor in Chief Views

Drugmaker RedHill Biopharma owes repayments to 340B covered entities, a finalized HRSA audit found.

A fourth drugmaker owes repayment to 340B covered entities, according to final audits posted this week by federal officials. RedHill [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Astellas Ends 340B Contract Pharmacy Restrictions in Arkansas and Louisiana

October 11, 2023 William Newton, Associate Editor/Senior Writer Views

Astellas is the third drugmaker to loosen or end its 340B contract pharmacy restrictions in Arkansas and Louisiana in response to state laws.

Drugmaker Astellas has ended its 340B contract pharmacy restrictions in both Arkansas and Louisiana in response to state laws that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Drugmaker Overcharge Fines for 340B Drugs Reach Nearly $7,000

October 11, 2023 Rich Daly, Editor in Chief Views

Drugmaker overcharge fines, which the Department of Health and Human Services assesses, recently increased to nearly $7,000.

The federal fine for each instance of drugmaker overcharges for 340B covered entities recently increased to nearly $7,000. The fine [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Drugmakers Post Refund Notices on HRSA Website

October 11, 2023 Rich Daly, Editor in Chief Views

Drugmakers Noven and Granules each owe refunds to 340B providers, according to notices posted on HRSA's Office of Pharmacy Affairs website.

Noven Pharmaceuticals and Granules Pharmaceuticals owe refunds to 340B providers, according to notices posted on the Health Resources and Services [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

BMS Expands 340B Contract Pharmacy Conditions, Including for Grantees

October 6, 2023 Tom Mirga, Editor at Large Views

Bristol Myers Squibb has announced updates to its conditions on pharmaceutical sales involving contract pharmacies.

Bristol Myers Squibb (BMS) announced updates to its conditions on pharmaceutical sales involving contract pharmacies, effective Nov. 1. BMS outlined [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Novartis Offering 340B Refunds on Two Diagnostic Radiopharmaceuticals

October 5, 2023 Tom Mirga, Editor at Large Views

Drugmaker Novartis is offering refunds to 340B covered entities on certain purchases of two radiopharmaceuticals.

Drug manufacturer Novartis is offering 340B covered entities refunds on purchases of two imaging agents, partly contingent on whether an [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Category: Pharma Industry

Paper Warns on Duplicate Discounts from 340B Ceiling Price, Medicare Maximum Price

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Eisai’s New 340B Contract Pharmacy Restrictions to Exclude Arkansas and Louisiana

Please Login or Become a Paid Subscriber to View this Content

If you are already a

New BMS Contract Pharmacy Policy May Target Hospital Self-Distribution, Say Attorneys

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Novo Nordisk Files Suit to Block $100,000 Arkansas Fine for 340B Contract Pharmacy Violations

Please Login or Become a Paid Subscriber to View this Content

If you are already a

HRSA Audit Finds Fourth Drugmaker Owes Refunds

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Astellas Ends 340B Contract Pharmacy Restrictions in Arkansas and Louisiana

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Drugmaker Overcharge Fines for 340B Drugs Reach Nearly $7,000

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Two Drugmakers Post Refund Notices on HRSA Website

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

BMS Expands 340B Contract Pharmacy Conditions, Including for Grantees

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Novartis Offering 340B Refunds on Two Diagnostic Radiopharmaceuticals

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live